home-hero-image-mobile

Vaccine Innovation.
Beyond Convention.

We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep and periodontitis to protect every child born and every adult at risk across the globe.

See Our Mission
Image for Pushing the Boundaries of What's Possible

Pushing the Boundaries of What’s Possible

Despite widespread vaccination with current pneumococcal conjugate vaccines (PCVs), there is an abundance of non-vaccine strains of the Streptococcus pneumoniae bacteria causing significant morbidity and mortality, underscoring the importance of advancing our lead program, VAX-24, a 24-valent PCV candidate. VAX-24 is currently the broadest-spectrum PCV in development and one of the most complex biologics ever created.

Re-Engineering How Vaccines are Made

We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our XpressCF™ cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving immunogenicity.
Image for Pushing the Boundaries of What's Possible

Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines

Our PCV franchise is intended to improve upon existing pneumococcal vaccines by covering the serotypes responsible for most of the remaining pneumococcal disease currently in circulation. Following VAX-24, we are developing VAX-XP, a PCV candidate with an expanded breadth of coverage of greater than 30 strains of pneumococcal disease. Additional vaccine candidates in preclinical development target Group A Strep bacteria and periodontitis.

Latest News

01

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and
02

Vaxcyte to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host
03

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten

Careers: Built to Scale with Purpose

Looking for higher aspirations to ignite your mind and inspire your heart? Then join a team that brings grit and grace to the challenge of protecting every human from the consequences of endemic bacterial infections.